Sydney M Crago

Glenn Yiu, MD, PhD, was chosen for this grant. Yiu is a retinal specialist and clinician-scientist currently a professor of ophthalmology at the University of California, Davis.

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).

The FDA previously granted Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug designation to ATSN-101 for the treatment of LCA1.

The commercial release of OcuLenz is planned for the first half of 2024. Ocutrx is collaborating with Medicare and insurance providers to ensure the headset's affordability and accessibility.

The kiosk is the first to offer self-service retinal imaging, empowering individuals to capture their own images.

This trial is a multi-center, open-label safety and tolerability study enrolling 30 patients to evaluate a low and high dose of AVD-104 with 3-month follow-up.

Updates include expected timelines for trials for the treatment of wet AMD, DME, GA, and inherited retinal diseases.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

This partnership will provide Greater Tampa Bay community with services for the treatment of uveitis and retina care.

If granted, this device would be assigned an official classification as a Class II device with special controls.

Data will be shared in early 2024 regarding this potential treatment of diabetic retinopathy via eye drop.

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

Catch up on a few of our top stories and ones you may have missed in 2023

The suspension is unrelated to product quality and will lift in February of 2024.

Government focus on preventing blindness as well as rising elderly population are key drivers behind this growth.

Boneva is an experienced surgeon skilled in trauma, surgical critical care, emergency surgery, and acute care surgery.

Umedaptanib pegol has potential to improve outcomes if used as a first-line medication prior to patients receiving treatments targeting VEGF.

Sblendorio brings decades of experience in the ophthalmic industry to his position on the Nanoscope board as the company continues to move forward in their commitment to retinal diseases.

The partnership will further the effort to bring VGX-0111, a gene therapy treatment for AMD to patients and providers.

The study saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

The company’s lead ophthalmology candidate, EXN407, has the potential to be the first topical treatment for DR/DME.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD, but this research more clearly shows how cells are affected.

The augmented reality headset compensates for central vision loss to enhance the visual clarity of patients with age-related macular degeneration and other conditions such as Stargardt disease.

The Vision Council’s Q3 Provider Insights study shows the sentiments of eye care providers nationwide as they manage practices and patient care.

Sophie Bakri, MD, spoke with the Ophthalmology Times team about her presentation at this year's American Academy of Ophthalmology meeting titled, "Real world outcomes and treatment patterns with faricimab and AMD FA retina."

Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.

Rob Thornhill, CEO of Centricity Vision spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

Marco A. Zarbin, MD, spoke with the Ophthalmology Times team about conducting a post-hoc analysis of the YOSEMITE and RHINE clinical trials and presenting the results at this year's American Academy of Ophthalmology meeting.

Mathew MacCumber, MD, PhD, FASRS, spoke with Modern Retina about his presentation at the recent Retina Society meeting in New York City titled, "0.19 mg Fluocinolone Acetonide (FAc) Implant Improves Vision and Treatment Burden in Patients with Diabetic Macular Edema: The PALADIN Study."